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Abstract
Proliferationoftype IIpneumocytesmaybethemost sensitivepathologicalindicatorof alveolitis, andthedensityoftype II
pneumocytesreflecting the severityoftherecent alveolardamage.Twenty-nine patientswere divided intothree groups
by the severity of ground-glass opacities on the CT scans; the severe (acute), the moderate (subacute) and the mild
(chronic) groups.We compared the density of type II pneumocytes in the transbronchial lung biopsy specimens and cell
analysis of bronchoalveolar lavage (BAL) fluidwith the ground-glass opacities.Clinical and laboratory findings and BAL
fluid analysis also correspondedwellwith this grouping.Type II pneumocytes were selectively stainedwith an antibody
against Thomsen^Friedenreich and the density of the type II pneumocytes was expressed as the number per1mm al-
veolar septal length.The densities of the type II pneumocytes in the severe, the moderate, the mild, and the control
groups were 21.271.1,14.477.2,11.073.3 and 7.570.9/mm, respectively.There were significant differences between the
acutegroupandtheother threegroups, andbetweenthecontrolandchronicgroups.Thedensityoftype IIpneumocytes
is a useful index for evaluatingalveolardamage even inmild alveolitis.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
Keywords interstitial pneumonia; pneumocytes; alveolitis; lung biopsy; bronchoscopy.INTRODUCTION
It is di⁄cult to evaluate recent alveolar damage in di¡use
interstitial lung diseases, especially in idiopathic pulmon-
ary ¢brosis (IPF), in which slight but continuous alveolar
injury persists.Chest CT ¢ndings, analysis of bronchoal-
veolar lavage £uid (BALF), respiratory function tests,
and measurements of lactate dehydrogenase and KL-6
in serum have been used clinically as ways of assessing
alveolar damage (1^4). However, these ¢ndings are not
sensitive enough to detectmild alveolar injury.
Di¡use interstitial lung diseases have been diagnosed
on the basis of pathological ¢ndings in the specimens ob-
tainedby open lung biopsy or by video-assisted thoraco-
scopic lung biopsy (5), and their activity levels also haveReceived 28 December 2001, accepted in revised form 4 June 2002
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Japan.been evaluated pathologically (6). One shortfall of such
lung biopsies is that they cannot usually be repeated for
reevaluation. Although transbronchial lung biopsy
(TBLB) via a ¢beroptic bronchoscope is a repeatable
method for pathological evaluation, its usefulness is lim-
ited because the samples are too small to allow us to as-
sess the interstitial changes throughout the lung as a
whole. If TBLB specimens do actually give a re£ection of
the severity of the alveolar damage present,TBLB could
prove especially valuable in forming the treatment of dif-
fuse interstitial lung diseases.
Proliferation of type II pneumocytes is one of themost
sensitive pathological ¢ndings in cases of alveolar injury
(7,8). In the reparative phase, type II pneumocytes prolif-
erate, replacing sloughed type I pneumocytes. In fact,
proliferation or hyperplasia of type II pneumocytes
develops approximately 3^7 days after injury in
cases of di¡use alveolar damage (9). A similar repair
process is observed in chronic ¢brosing lung diseases
(10,11).
In this study, we examined the proliferation of type II
pneumocytes in specimens obtained by TBLB from pa-
tients with interstitial lung diseases and assessed its use-
fulness in the assessment of alveolar damage.
TBLBSPECIMENSREFLECTINGALVEOLITIS 81MATERIALSANDMETHODS
Materials
Twenty-nineTBLB specimens were obtained from 29 pa-
tients among 536 who underwent ¢beroptic broncho-
scopy in Shinshu University Hospital between Jan. 1996
and Dec.1997. All 29 patients showed interstitial opaci-
ties on chest CT scans, and TBLB and BAL were per-
formed on the same day. The 29 patients were divided
into three groups: seven patients showing bilateral
marked ground-glass opacities that had developed over
a1-week period [severe (acute) group],14 exhibiting par-
tial ground-glass opacities that had developed over sev-
eral weeks [moderate (subacute) group], and eight with
slight reticulonodular and ground-glass opacities that
had been gradually progressing for several years [mild
(chronic) group]. The acute group comprised four with
hypersensitive pneumonia, one bronchiolitis obliterans
organizing pneumonia (BOOP), one eosinophilic pneu-
monia, and one collagen vascular disease. The subacute
group comprised ¢ve BOOP, ¢ve collagen vascular dis-
ease, two eosinophilic pneumonia and two hypersensi-
tive pneumonia. The chronic group comprised ¢ve
idiopathic pulmonary ¢brosis and three collagenvascular
disease.We also examined ¢veTBLB specimens (biopsy
control group) and ¢ve necropsy specimens (necropsy
control group) as controls.The ¢vepatients in thebiopsy
control group, who had no CT ¢ndings, were biopsied
for the diagnosis of possible sarcoidosis because of uvei-
tis. And in fact, none of their ¢ndings including ¢ndings
from histology of TBLB specimens and BALF analysis
were indicative of sarcoidosis. The ¢ve necropsy speci-
mens were obtained frompatients without lung disease.
Lightmicroscopic study
Biopsy and necropsy tissues were ¢xed in 20% bu¡ered
formalin for 24h.Each specimenwas dehydrated through
graded alcohols, cleared in xylene, and embedded in par-
a⁄n.Three-micron serial sections were stainedwith he-
matoxylin and eosin (HE), and with antibodies against
Thomsen-Friedenreich (TF) (DAKO, Glostrup, Den-
mark) after sialidase digestion.
Sialidase digestion pretreatment (from Arthrobactor
ureafaciens, Nakarai Chemicals, Kyoto, Japan) (1 unit/ml
in 0.05M phosphate bu¡er, pH7.0) was carried out at
371C for 4h before immunostaining forTF antigen. The
sections were incubated in 0.3% hydrogen peroxide in
methanol for 30min to remove endogenous peroxidase
activity.They were then incubated in phosphate bu¡ered
saline (PBS) containing 1% bovine serum albumin and
monoclonal antibodies (anti-TF 1:100) at 41C for 18h.
After rinsing in PBS, the sections were incubated in solu-
tions containinghorseradishperoxidase-conjugatedgoat
anti-mouse IgG antibody (diluted to 1:100 in PBS).After further rinsing in PBS, antibody binding sites
were visualized using a solution containing 0.02%
3,30diaminobenzidine (Wako Pure Chemical, Tokyo, Ja-
pan) and 0.005% hydrogen peroxide in phosphate bu¡er.
Counterstaining was carried out using hematoxylin.
Density of type II pneumocytes
After staining with an anti-TF antibody, ¢ve areas of
0.58 0.44mm in each slide were randomly selected
and photographed using a digital camera (SONYDKC
5000, SONY, Tokyo, Japan). Type II pneumocytes were
counted, and the total length of the alveolar septum
was measured using NIH-Image 1.60/pcc software (Na-
tional Institutes of Health, U.S.A.) obtained from sippy.-
nimh.nih.gov via anonymous FTP.The number per 1mm
of alveolar septal length was taken as the density of the
type II pneumocytes.
Statistic analysis
Data are expressed as the mean7SD. Di¡erences were
taken to be statistically signi¢cant when the probability
valuewas less than 0.05 (unpaired t-test)
RESULTS
The clinical data for the patients in the four biopsy
groups are summarized inTable 1.There were no signi¢-
cant di¡erences in age, pulmonary function tests, or
blood gas analysis.C-reactive protein and the number of
white blood cells also showed no signi¢cant di¡erences
among the groups, and did not rise to a level indicating
bacterial pneumonia.The serum level of lactate dehydro-
genasewas high in all three lung-disease groups, but not
in the biopsy control group, and that in the severe group
was signi¢cantly higher than that in themoderate group.
The intervalbetween the onsetof respiratory symptoms
and the performance of ¢beroptic bronchoscopy was
signi¢cantly shorter for the severe andmoderate groups
than for themild group.
Theresults of theBALF analysis are summarizedin Ta-
ble 2. Both the number and percentage of lymphocytes
were signi¢cantly higher in the three lung-diseasegroups
than in the biopsy control group.The number of lympho-
cytes was also signi¢cantly higher in the severe group
than in the mild group. The number of lymphocytes ex-
pressing HLA-DRwas signi¢cantly greater in the severe
group than in the other three groups.Total protein and
albumin were both greater signi¢cantly in the severe
group than in the mild group. Lactate dehydrogenase
was signi¢cantly elevated in the three lung-disease
groups by comparisonwith the biopsy control group.
After sialidase digestion, TF antibody stained the api-
cal surface of type II pneumocytes in the normal lung
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82 RESPIRATORYMEDICINE(Fig.1). Although the alveolar surfacewas slightly stained
in the peripheral lung showing alveolitis, this staining se-
quence enabled us to recognize and to count type II
pneumocytes more easily than HE staining. The density
in the necropsy control groupwas 6.670.7/mm.
Thevalues obtained for the density of type II pneumo-
cytes in the severe (Fig. 2), moderate, mild, and biopsy
control groups were 21.2711.1, 14.477.2, 11.073.3 and
7.570.9/mm, respectively (Fig. 3). There was no signi¢-
cantdi¡erencebetween thebiopsy andnecropsy control
groups.The density was signi¢cantly higher in the severe
andmild groups than that in the control group.The den-
sity in the severe groupwas also signi¢cantly higher than
that in themoderate group or themild group.The mod-
erate group did not show signi¢cant di¡erence statisti-
cally from the biopsy control (P=0.0516), and there was
no signi¢cant di¡erence between the moderate and the
mild groups (P=0.228).
DISCUSSION
The density of the type II pneumocytes, which was ex-
pressed as the number per 1mm alveolar septal length,
is a useful pathological index for evaluating alveolar da-
mage even in mild (chronic) interstitial lung diseases. It
correspondedwellwith the severityof ground-glass opa-
cities on the chest CTscans.
Proliferation of type II pneumocytes is one of themost
sensitivepathological indicators of alveolitis after various
lung injuries. Proliferation of type II pneumocytes is ob-
served in the reparativephase after alveolar damage (12),
and alveolar lining-cell hyperplasia develops approxi-
mately 3^7 days after such injury (9). However, this
pathological ¢nding is subjective, with di¡erent patholo-
gists gaining di¡erent impressions, and there are no cri-
teria to guide us in grading their proliferation. The
densityof type II pneumocytes as calculatedhere is a use-
ful index of their proliferation, which itself indicates re-
cent alveolar injury.
The density of type II pneumocytes inTBLB specimens
may directly re£ect the severity of recent alveolar da-
mage.Thepathological features of interstitial pneumonia
are mainly the presence of cellular in¢ltrates, epithelial
necrosis and proliferation, capillary and epithelial peri-
cytes, air space cellular exudates, granulomas, necrosis,
organizing and scarring and honeycombing (12). How-
ever, proliferation of type II pneumocytes may be the
most sensitive among these ¢ndings, and it could detect
evenmild lung injury in the present study.
Counting the number of type II pneumocytes per
1mm alveolar septal length enabled us to easily detect a
slight proliferation of type II pneumocytes even in idio-
pathic pulmonary ¢brosis and chronic interstitial pneu-
monia in collagen vascular disease. Immunostaining with
an antibody against TF antigen after sialidase digestion
FIG. 1. Normalbiopsy specimen, immunostainingwith anti-TF
antibodyafter sialidase digestion.The apical surface of sometype
IIpneumocytes is stained.
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TBLB SPECIMENSREFLECTINGALVEOLITIS 83selectively stained the apical surface of the type II pneu-
mocytes (13), and use of this sequence enabled us to de-
tect and count type II pneumocytes with ease under the
light microscope. There was signi¢cant di¡erence be-
tween the control and chronic groups in this study. How-
ever, the moderate group was not signi¢cantly di¡erent
from the biopsy control because one case showed very
low density of type II pneumocytes.
Earlier,we concluded that a referencerange for type II
pneumocyte densitymightbe 6.5^8.5 per1mmof alveo-
lar septal length for biopsy specimens ordinarily pro-
cessed (14). In the present study, the densities in the
biopsy and necropsy control groups were within this
range. Their standard deviations were small, and tissue
¢xation did not seem to greatly alter the range of values
obtained. Other ways of counting may be less reliable:
for example, expression type II pneumocytes per squareFIG. 2. Biopsy specimen from a patient with interstitial pneu-
monia inthe severegroup, immunostainingwith anti-TFaftersia-
lidase digestion. The apical surface of type II pneumocytes is
stained.
FIG. 3. Densityof type IIpneumocytes.
Necropsy control: necropsy control group, Biopsy control:
biopsy control group, mild: mild group, moderate: moderate
group, severe: severe group;
*: signi¢cantdi¡erence (Po0.05)
**:signi¢cantdi¡erence (Po0.0001)
84 RESPIRATORYMEDICINEof given size on the slide may be in£uenced by the ¢xa-
tion conditions, and counting type II pneumocytesper al-
veolus has the drawback that recognizing alveoli as such
canbe di⁄cult because alveoli do not form complete cir-
cles. Expressing the number of type II pneumocytes per
1mmof alveolar septal length seems to us to be a reliable
way of counting type II pneumocytes.
Type II pneumocytes are not distributed uniformly on
the alveolar wall.We demonstrated three dimensionally
that type II pneumocytes were preferentially located on
thick elastic ¢bers forming themain alveolar framework
(15).This ¢nding helps to clarify the descriptions given by
Fawcett and Spencer of type II pneumocytes being com-
monly located near the septa of adjoining alveoli (16,17).
This irregular distribution of type II pneumocytes does
not a¡ect values obtained for density, provided type II
pneumocytes are counted in a large enough area. We
think that ¢ve areas of 0.58 0.44mmeach are su⁄cient
to obtain a reliable estimate of the density of type II
pneumocytes.
Ground-glass opacityre£ects thehistologic ¢ndings of
alveolitis at open lung biopsy (18), and it can re£ectmini-
mal thickening of the pulmonary interstitium or alveolar
wall, or the presence of cells or £uid within the alveolar
air spaces (19). An elevation of lactate dehydrogenase in
serum (3) and a decrease in the di¡using capacity of car-
bon monoxides indicate interstitial change. Both the
number and percentage of lymphocytes in BALF indi-
cated lymphocytic alveolitis. An increase in lymphocytes
expressing HLA-DR shows activation of lymphocytes(20), and an increase in the total protein and albumin in
BALF demonstrates increased permeability between al-
veoli and capillary as a result of alveolar septal damage.
Although these ¢ndings demonstrate alveolardamagein-
directly, the density of the type II pneumocytes
showed recent alveolar damage directly and semi-quan-
titatively.
The usefulness of TBLB is thought to be limited and
the specimen size obtained is thought to be too small
for the evaluation of the activity of the interstitial pneu-
monia.The density of the type II pneumocytesmaymore
precisely support the evaluation of the activity by CT,
BALF or both examinations. An index of the density of
type II pneumocytes permits sensitive detection of re-
cent alveolar damage in combination with the above ex-
aminations which can evaluate thewhole lung.
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